Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Morning CBAI'ers! I have an appointment and must step out for most of the day but watch out for this week! CBAI is smoking ;)
CBAI- PROFITING MEDICAL SECTOR! THERE ARE MANY MANY ADVANTAGES FOR CORD BLOOD AND BEING IN MEDICINE I CAN SAY FOR CERTAIN THAT CORD BLOOD HAS THE ABILITY TO HELP PEOPLE IN MANY WAYS!
Look out for my full informational report so that everyone here can see what I see as I believe this stock is headed much higher very very soon ;)
CBAI- I will be posting some information soon on this company as I believe this has the potential to go like some of the other stocks I am in. My belief is based on my findings which I will be more then happy to share with everyone here as soon as I jot them down in an orderly format.
CBAI- Picked up some shares today! Looking to pick up some more soon big things coming for CBAI I hear ;)
MCET (MultiCell Technologies, Inc.) I am hanging on to my shares tight because I know what MCET has soon enough based on my research and DD! :)
**MCET MUST READ DD FOR THOSE WHO HAVEN'T READ THIS YET**
MCET (MultiCell Technologies, Inc.)
MCET DD:
1) addresses "unmet" medical needs for the treatment of neurological disorders, hepatic disease and cancer which means the company is creating different treatments that are not currently pre-existing.
2) Undervalued stock with partners...BRISTOL MYERS, PFIZER, MBI ,CORNING + more!
The preliminary tests have tested successful and MCET is on the right track which means room for great expansion!
3) La Jolla recently purchased shares of this stock, which means big things may be cooking!
4) In order for the therapies to be FDA approved, successful testing has to be implemented and a HUGE leap for MCET is the initiation of MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. No current treatment exists for PMSF and with positive results in phase 1, MCET has now moved to phase 2 which shows they are definitely on the right track to great success!
5) Furthermore, many many pharmaceutical companies have taken off to cents and dollars we have sat and analyzed MCET and have formed our own opinion that MCET appears highly undervalued for its stage in the pharmaceutical industry. The pharmaceutical industry is a billion dollar industry and because MCET is currently in active phase 2 for the drug for PMSF (not currently available anywhere) MCET has a leverage above other stocks and other pharmaceutical companies in this way and others.
CRITICAL READ: OVERVIEW (BELOW)
The brain and spinal cord (CNS) is protected by Myelin sheath. In individuals with MS the Myelin sheath is destroyed by the body's own immune system and symptoms become apparent according to the severity of it. Once this destruction occurs, scar tissue forms on the damaged area and regular tissue does not regrow. This means that signals sent to and from the brain and spinal cord may be disrupted causing issues in coordination and such. In addition to this, Multiple Sclerosis is a leading Musculoskeletal disease that is effecting more and more people as time passes. This is why companies such as MCET, which are creating medications for diseases like MS, can become profitable in the future. The pharmaceutical industry is worth billions and there is a great need for research and medications for diseases that are becoming increasingly prevalent. We firmly believe MCET (MultiCell Technologies, Inc.) is headed in the right direction.
MCET focuses in on the fatigue related to MS: Primary Multiple Sclerosis-Related Fatigue (PMSF)
with effects a majority of individuals with Multiple Sclerosis and often leads to decreased ability to function and ultimately even a further reduction of health. How exactly does this happen? Well, people with MS have damaged myelin sheath (the protective covering of nerves in the CNS (Brain and Spinal Cord). The nerve signals cannot adequately reach their destination and may continue firing which can lead to fatigue. Currently there is no drug available for this fatigue and one of the things MCET is doing is working with researchers to create a drug for this.
E.g., MultiCell Technologies is working to Modulate “the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis”
In addition to working to create treatments for PMSF, MCET is also doing a number of things including the following for the treatment of Cancer:
Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.
Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.
Both Multiple sclerosis and Cancer are issues that are bring increasingly faced by many individuals around the world. MCET is working to find therapies and has already gained considerable depth in their work which is proof they may very well be on their way to great success!
Please read the following for more in depth information: http://www.multicelltech.com/Discovery-Platform-and-Disease-Targets
Many cases are found when patients are coming in to the OR for other problems. MCET has medications which have tested successfully. The pharmaceutical industry is worth billions and both multiple sclerosis and cancer fighting treatments are needed more and more, which makes Multicell Technologies, Inc. even more valued then ever before.
**MCET HUGE DD MUST READ**
MCET (MultiCell Technologies, Inc.)
MUST READ INFO:
1) addresses "unmet" medical needs for the treatment of neurological disorders, hepatic disease and cancer which means the company is creating different treatments that are not currently pre-existing.
2) Undervalued stock with partners...BRISTOL MYERS, PFIZER, MBI ,CORNING + more!
The preliminary tests have tested successful and MCET is on the right track which means room for great expansion!
3) La Jolla recently purchased shares of this stock, which means big things may be cooking!
4) In order for the therapies to be FDA approved, successful testing has to be implemented and a HUGE leap for MCET is the initiation of MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. No current treatment exists for PMSF and with positive results in phase 1, MCET has now moved to phase 2 which shows they are definitely on the right track to great success!
5) Furthermore, many many pharmaceutical companies have taken off to cents and dollars we have sat and analyzed MCET and have formed our own opinion that MCET appears highly undervalued for its stage in the pharmaceutical industry. The pharmaceutical industry is a billion dollar industry and because MCET is currently in active phase 2 for the drug for PMSF (not currently available anywhere) MCET has a leverage above other stocks and other pharmaceutical companies in this way and others.
CRITICAL READ: OVERVIEW (BELOW)
The brain and spinal cord (CNS) is protected by Myelin sheath. In individuals with MS the Myelin sheath is destroyed by the body's own immune system and symptoms become apparent according to the severity of it. Once this destruction occurs, scar tissue forms on the damaged area and regular tissue does not regrow. This means that signals sent to and from the brain and spinal cord may be disrupted causing issues in coordination and such. In addition to this, Multiple Sclerosis is a leading Musculoskeletal disease that is effecting more and more people as time passes. This is why companies such as MCET, which are creating medications for diseases like MS, can become profitable in the future. The pharmaceutical industry is worth billions and there is a great need for research and medications for diseases that are becoming increasingly prevalent. We firmly believe MCET (MultiCell Technologies, Inc.) is headed in the right direction.
MCET focuses in on the fatigue related to MS: Primary Multiple Sclerosis-Related Fatigue (PMSF)
with effects a majority of individuals with Multiple Sclerosis and often leads to decreased ability to function and ultimately even a further reduction of health. How exactly does this happen? Well, people with MS have damaged myelin sheath (the protective covering of nerves in the CNS (Brain and Spinal Cord). The nerve signals cannot adequately reach their destination and may continue firing which can lead to fatigue. Currently there is no drug available for this fatigue and one of the things MCET is doing is working with researchers to create a drug for this.
E.g., MultiCell Technologies is working to Modulate “the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis”
In addition to working to create treatments for PMSF, MCET is also doing a number of things including the following for the treatment of Cancer:
Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.
Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.
Both Multiple sclerosis and Cancer are issues that are bring increasingly faced by many individuals around the world. MCET is working to find therapies and has already gained considerable depth in their work which is proof they may very well be on their way to great success!
Please read the following for more in depth information: http://www.multicelltech.com/Discovery-Platform-and-Disease-Targets
Many cases are found when patients are coming in to the OR for other problems. MCET has medications which have tested successfully. The pharmaceutical industry is worth billions and both multiple sclerosis and cancer fighting treatments are needed more and more, which makes Multicell Technologies, Inc. even more valued then ever before.
MCET (MultiCell Technologies, Inc.) Phase 2 MSRF DRUG FOR Multiple Sclerosis in the works! No other drug of its kind currently exists! Moreover, La Jolla Cover Investments just bought 129,208,041 shares on Feb 7th and just filed their SC 13G on Feb 13th= This is HUGE!I think this can go MULTI-PENNIES!
HAHA very funny! I am hanging on to my MCET SHARES TIGHT! I KNOW WHAT I OWN! $$$ They attempt this trick every time and its real funny when they can't even spell correctly!
MCET- **MUST READ**PHASE 2 OF MSRF COMPLETED! NO BIOTECH COMPANY CURRENTLY HAS A DRUG FOR THIS! THIS IS HUGE!!! THERE IS NO COMPETITION FOR THIS DRUG WHICH MEANS ONCE THE PHASES ARE COMPLETE I BELIEVE THIS COULD VERY WELL SKYROCKET INTO DOLLARS AND THESE PRICES WILL BE A JOKE! ;)
MCET(MultiCell Technologies, Inc.)**INTERESTING FINDS**-PLEASE STICKY THIS!
FINDS:
MCET:
1) addresses "unmet" medical needs for the treatment of neurological disorders, hepatic disease and cancer which means the company is creating different treatments that are not currently pre-existing.
2) Undervalued stock with partners...BRISTOL MYERS, PFIZER, MBI ,CORNING + more!
The preliminary tests have tested successful and MCET is on the right track which means room for great expansion!
3) La Jolla recently purchased shares of this stock, which means big things may be cooking! Why would someone purchase vast amounts of stock?....
4) In order for the therapies to be FDA approved, successful testing has to be implemented and a HUGE leap for MCET is the initiation of MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. No current treatment exists for PMSF and with positive results in phase 1, MCET has now moved to phase 2 which shows they are definitely on the right track to great success!
5) Furthermore, many many pharmaceutical companies have taken off to cents and dollars we have sat and analyzed MCET and have formed our own opinion that MCET appears highly undervalued for its stage in the pharmaceutical industry. The pharmaceutical industry is a billion dollar industry and because MCET is currently in active phase 2 for the drug for PMSF (not currently available anywhere) MCET has a leverage above other stocks and other pharmaceutical companies in this way and others.
CRITICAL READ: OVERVIEW (BELOW)
The brain and spinal cord (CNS) is protected by Myelin sheath. In individuals with MS the Myelin sheath is destroyed by the body's own immune system and symptoms become apparent according to the severity of it. Once this destruction occurs, scar tissue forms on the damaged area and regular tissue does not regrow. This means that signals sent to and from the brain and spinal cord may be disrupted causing issues in coordination and such. In addition to this, Multiple Sclerosis is a leading Musculoskeletal disease that is effecting more and more people as time passes. This is why companies such as MCET, which are creating medications for diseases like MS, can become profitable in the future. The pharmaceutical industry is worth billions and there is a great need for research and medications for diseases that are becoming increasingly prevalent. We firmly believe MCET (MultiCell Technologies, Inc.) is headed in the right direction.
MCET focuses in on the fatigue related to MS: Primary Multiple Sclerosis-Related Fatigue (PMSF)
with effects a majority of individuals with Multiple Sclerosis and often leads to decreased ability to function and ultimately even a further reduction of health. How exactly does this happen? Well, people with MS have damaged myelin sheath (the protective covering of nerves in the CNS (Brain and Spinal Cord). The nerve signals cannot adequately reach their destination and may continue firing which can lead to fatigue. Currently there is no drug available for this fatigue and one of the things MCET is doing is working with researchers to create a drug for this.
E.g., MultiCell Technologies is working to Modulate “the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis”
In addition to working to create treatments for PMSF, MCET is also doing a number of things including the following for the treatment of Cancer:
Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.
Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.
Both Multiple sclerosis and Cancer are issues that are bring increasingly faced by many individuals around the world. MCET is working to find therapies and has already gained considerable depth in their work which is proof they may very well be on their way to great success!
Please read the following for more in depth information: http://www.multicelltech.com/Discovery-Platform-and-Disease-Targets
Many cases are found when patients are coming in to the OR for other problems. MCET has medications which have tested successfully. The pharmaceutical industry is worth billions and both multiple sclerosis and cancer fighting treatments are needed more and more, which makes Multicell Technologies, Inc. even more valued then ever before.
MCET (MultiCell Technologies, Inc.)HUGE REVISED DD
1) addresses "unmet" medical needs for the treatment of neurological disorders, hepatic disease and cancer which means the company is creating different treatments that are not currently pre-existing.
2) Undervalued stock with partners...BRISTOL MYERS, PFIZER, MBI ,CORNING + more!
The preliminary tests have tested successful and MCET is on the right track which means room for great expansion!
3) La Jolla recently purchased shares of this stock, which means big things may be cooking!
4) In order for the therapies to be FDA approved, successful testing has to be implemented and a HUGE leap for MCET is the initiation of MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. No current treatment exists for PMSF and with positive results in phase 1, MCET has now moved to phase 2 which shows they are definitely on the right track to great success!
5) Furthermore, many many pharmaceutical companies have taken off to cents and dollars we have sat and analyzed MCET and have formed our own opinion that MCET appears highly undervalued for its stage in the pharmaceutical industry. The pharmaceutical industry is a billion dollar industry and because MCET is currently in active phase 2 for the drug for PMSF (not currently available anywhere) MCET has a leverage above other stocks and other pharmaceutical companies in this way and others.
CRITICAL READ: OVERVIEW (BELOW)
The brain and spinal cord (CNS) is protected by Myelin sheath. In individuals with MS the Myelin sheath is destroyed by the body's own immune system and symptoms become apparent according to the severity of it. Once this destruction occurs, scar tissue forms on the damaged area and regular tissue does not regrow. This means that signals sent to and from the brain and spinal cord may be disrupted causing issues in coordination and such. In addition to this, Multiple Sclerosis is a leading Musculoskeletal disease that is effecting more and more people as time passes. This is why companies such as MCET, which are creating medications for diseases like MS, can become profitable in the future. The pharmaceutical industry is worth billions and there is a great need for research and medications for diseases that are becoming increasingly prevalent. We firmly believe MCET (MultiCell Technologies, Inc.) is headed in the right direction.
MCET focuses in on the fatigue related to MS: Primary Multiple Sclerosis-Related Fatigue (PMSF)
with effects a majority of individuals with Multiple Sclerosis and often leads to decreased ability to function and ultimately even a further reduction of health. How exactly does this happen? Well, people with MS have damaged myelin sheath (the protective covering of nerves in the CNS (Brain and Spinal Cord). The nerve signals cannot adequately reach their destination and may continue firing which can lead to fatigue. Currently there is no drug available for this fatigue and one of the things MCET is doing is working with researchers to create a drug for this.
E.g., MultiCell Technologies is working to Modulate “the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis”
In addition to working to create treatments for PMSF, MCET is also doing a number of things including the following for the treatment of Cancer:
- Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
- Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.
Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.
Both Multiple sclerosis and Cancer are issues that are bring increasingly faced by many individuals around the world. MCET is working to find therapies and has already gained considerable depth in their work which is proof they may very well be on their way to great success!
Please read the following for more in depth information: http://www.multicelltech.com/Discovery-Platform-and-Disease-Targets
Many cases are found when patients are coming in to the OR for other problems. MCET has medications which have tested successfully. The pharmaceutical industry is worth billions and both multiple sclerosis and cancer fighting treatments are needed more and more, which makes Multicell Technologies, Inc. even more valued then ever before.
MCET-(MultiCell Technologies, Inc.) ** PHASE 2 SUCCESSFULLY COMPLETED FOR MSRF NO OTHER DRUG LIKE THIS EXISTS CURRENTLY!** I believe this is huge and gives leverage over other biotechnology companies!
**HUGE MCET DD MUST READ**:1) addresses "unmet" medical needs for the treatment of neurological disorders, hepatic disease and cancer which means the company is creating different treatments that are not currently pre-existing.
2) Undervalued stock with partners...BRISTOL MYERS, PFIZER, MBI ,CORNING + more!
The preliminary tests have tested successful and MCET is on the right track which means room for great expansion!
3) La Jolla recently purchased shares of this stock, which means big things may be cooking!
4) In order for the therapies to be FDA approved, successful testing has to be implemented and a HUGE leap for MCET is the initiation of MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. No current treatment exists for PMSF and with positive results in phase 1, MCET has now moved to phase 2 which shows they are definitely on the right track to great success!
5) Furthermore, many many pharmaceutical companies have taken off to cents and dollars we have sat and analyzed MCET and have formed our own opinion that MCET appears highly undervalued for its stage in the pharmaceutical industry. The pharmaceutical industry is a billion dollar industry and because MCET is currently in active phase 2 for the drug for PMSF (not currently available anywhere) MCET has a leverage above other stocks and other pharmaceutical companies in this way and others.
HUGE MCET DD:1) addresses "unmet" medical needs for the treatment of neurological disorders, hepatic disease and cancer which means the company is creating different treatments that are not currently pre-existing.
2) Undervalued stock with partners...BRISTOL MYERS, PFIZER, MBI ,CORNING + more!
The preliminary tests have tested successful and MCET is on the right track which means room for great expansion!
3) La Jolla recently purchased shares of this stock, which means big things may be cooking!
4) In order for the therapies to be FDA approved, successful testing has to be implemented and a HUGE leap for MCET is the initiation of MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. No current treatment exists for PMSF and with positive results in phase 1, MCET has now moved to phase 2 which shows they are definitely on the right track to great success!
5) Furthermore, many many pharmaceutical companies have taken off to cents and dollars we have sat and analyzed MCET and have formed our own opinion that MCET appears highly undervalued for its stage in the pharmaceutical industry. The pharmaceutical industry is a billion dollar industry and because MCET is currently in active phase 2 for the drug for PMSF (not currently available anywhere) MCET has a leverage above other stocks and other pharmaceutical companies in this way and others.
MCET- Hang tight this stock is ready for blastoff! The chart corrected itself and now its time for serious higher levels!;)
MCET- GOOD MORNING MCET' ERS! WE ARE READY TO ROLL TODAY TOWARDS HIGHER HIGHS! Some very very interesting findings ;) Compiling my research to be posted very soon! Dear naysayers who bashed when this stock was .0033 and the rest of us still held on because we knew: This stock took off from those levels and I believe they will soar very very soon! ... 'if ya can't beat em join em! .... ;)
MCET- No you trust me because I believe this will run! Not only that, but I have the facts to back it up and I will be posting them very very soon. There were naysayers last week but I kept telling them to look at the value in this stock and finally they saw it for themselves. Good luck in your trades, but this baby has everything possible going for it! ;)
MCET- For those that are unaware there are many great things going for MCET soon enough.I will be posting the juicy details soon! I am hanging on tight to my shares because I know the potential here... ;)
MCET-I believe this will gain higher levels well into the pennies fairly soon!
MCET- This company truly exists. Not only that but they have actual positive things going on behind the scenes...this will do anything but fall like a stone... if I remember correctly some people were saying this at .0032 levels and I remained optimistic because I knew the value of this company it took off to .0056 and I believe there is more to come very very soon! I'd hardly call that a falling stone..... ;)
MCET- Yes it is a sticky, but it is also a rather conceptual thing you see. The company is actively working to enhance their appeal among all other positive things in the works. The creation of a Facebook page is one way they are gaining attention from individuals like us and big companies. I know many individuals with businesses that have recently created Facebook pages and not only had their business flourish, but have gained tremendous wealth as a result of this often frowned upon way of advertising. Ask yourself this question... What big company does not have Facebook? Hmmm... I smell something big cooking... ;)
MCET- Good post and to add to that the company is finally working to enhance itself, which I believe adds definite value! There are many more things occurring with this stock as well which I will be posting soon. Glad to see you here!
MCET- I believe this is a real company that is undervalued. Not only that, but this is a biotech company with real confirmed things taking place! I will come on this board and say this again to naysayers once this stock takes off for good!
AGREED! I think we can see multi-pennies based on the facts associated with this stock and the confirmations!
MCET- Hello Pimping! Good to see you here! I believe MCET is ready for take off very very soon!
MCET- I firmly believe MCET will be in the multipennies soon! Biotech stock with the correct recipe for success!
lol MCET all the way!
I Agree!MCET looks ready and has the facts to back it up!
MCET- Many of us are holding because we know this will go much much higher! These prices are a joke- Multi-pennies and beyond is what I believe to be more accurate!
AGREED! MCET Looks Ready for Some Serious Highs Very Soon!
MCET- I believe multi-pennies are closer then we think!
MCET- During the following week!
AGREED!I think this will go easy multipennies soon!
Agreed!MCET has the correct concept for what is currently lacking in the medical industry and is working to fill this void with their technology. I believe that this is how MCET will take the upper hand in the near future!
MCET- The preliminary tests have tested successful and I believe MCET is on the right track towards great success!
MCET- Correct! The brain and spinal cord (CNS) are protected by Myelin sheath. In individuals with MS the Myelin sheath is destroyed by the body's own immune system and symptoms become apparent according to the severity of it. This means that signals sent to and from the brain and spinal cord may be disrupted causing issues in coordination and such. In addition to this, Multiple Sclerosis is a leading Musculoskeletal disease that is effecting more and more people as time passes.
This is why companies such as MCET, which are creating medications for diseases like MS, can become profitable in the future. The pharmaceutical industry is worth billions and being in the medicine I can say that there is a great need for research and medications for diseases that are becoming increasingly prevalent. This leads me to believe MCET (MultiCell Technologies, Inc.) is headed in the right direction.
MCET- Good Morning Everyone! I Believe MCET is the stock to be in. Pretty soon people will start chasing. Naysayers wont have a chance to say negative things because the REAL facts will start rolling out soon, in my opinion! ;)
MCET- This will fly. mark my words. Don't say I never told you so. This is my opinion. I tell you this based on the facts that are presented to me. I haven't posted much because I refuse to argue with naysayers. Tomorrow my post will be here so people can see what I see. Goodnight.
MCET- This company is headed in the right direction. I think in due time people will see how this is so.